Y-Biologics, Inc. (KOSDAQ:338840)

South Korea · Delayed Price · Currency is KRW

23,700

-750 (-3.07%)

At close: Apr 27, 2026

205.41% (1Y)

Market Cap	351.37B
Revenue (ttm)	2.91B
Net Income (ttm)	-42.02B
Shares Out	15.18M
EPS (ttm)	-2,822.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,480
Average Volume	249,594
Open	24,700
Previous Close	24,450
Day's Range	23,400 - 24,700
52-Week Range	7,310 - 38,000
Beta	0.99
RSI	40.49
Earnings Date	n/a

About Y-Biologics

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 a... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2007

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 338840

Full Company Profile

Financial Performance

In 2025, Y-Biologics's revenue was 2.91 billion, a decrease of -49.45% compared to the previous year's 5.76 billion. Losses were -42.02 billion, 552.4% more than in 2024.

Financial Statements

News

There is no news available yet.